目的:总结孙伟教授运用“益肾清利活血法”分期治疗慢性肾脏病的经验。方法:通过查阅孙伟教授及其弟子近20年有关肾脏病的著作、论文、科学研究成果,分析其诊治慢性肾脏病的理论特点和治疗方法;临证跟随孙教授抄方,学习了解孙伟教授益肾清利活血法的临床运用情况;运用慢性肾脏病管理系统,动态观察孙教授诊治的慢性肾脏病患者的治疗效果。通过了解孙教授临床、科研等,分析他的学术思想及临床运用,归纳总结孙伟教授治疗慢性肾脏病的病机特点和治则治法。结果:孙伟教授认为,慢性肾脏病病机总属“肾虚湿瘀”并贯穿整个肾脏病变过程中,治疗慢性肾脏病的大法应为“益肾清利活血”,即补肾健脾、清利化湿、活血和络,并形成了基本处方,根据慢性肾脏病的分期随症加减。这一治法可以有效提高临床疗效,改善慢性肾脏病的临床症状,提高患者的生活质量。结论:“肾虚湿瘀”是所有的慢性肾脏病共同的病机特点,“益肾清利活血”治法适用于所有的慢性肾脏病患者,但在慢性肾脏病的不同类型、病程发展的不同阶段、不同病证特点、病情轻重不一的情况下运用益肾、清利、活血的侧重点不尽相同。
Objective: To summarize Professor Sun Wei’s experience in the treatment of chronic kidney disease (CKD) by using the “YiShen QingLi Huoxue Therapy”. Method: Through reviewing the prescription, papers, and scientific research of Professor Sun Wei and his disciples about kidney disease for 20 years, to analyze the theoretical characteristics and therapeutic methods of CKD. We summarized Prof. Sun’s clinical application of Yishen Qingli Huoxue therapy. The CKD management system was used to dynamically observe the effect of patients with CKD receiving his treatment. We analyzed his academic experience on CKD. Result: Professor Sun Wei believes that the pathogenesis of CKD is always “kidney deficiency and damp stasis” and underlies the whole process of kidney disease. The main method for treating CKD is consisted of 3 therapies, tonifying kidney (YiShen), clearing dampness (Qingli), promoting circulation (Huoxue). He formed a core prescription and used herbs according to the different symptoms of CKD. This treatment can effectively improve clinical outcome, ameliorate the symptoms of CKD, and preserve the quality of life. Conclusion: “Kidney deficiency and damp stasis” is a common pathogenesis in CKD, and the “YiShen QingLi Huoxue” treatment is applicable to all patients with CKD. The use of Tonifying kidney, clearing dampness and promoting circulation therapy in different types of CKD should be based on different stages, disease syndrome characteristics and severity of illness.
孙伟,慢性肾脏病,肾虚湿瘀,益肾清利活血, Sun Wei Chronic Kidney Disease Kidney Deficiency and Dampness YiShen QingLi Huoxue Therapy孙伟教授基于“肾虚湿瘀”理论运用益肾清利活血法分期诊治慢性肾脏病的经验
陶佳音,高 坤,陆映丹,何伟明,孙 伟. 孙伟教授基于“肾虚湿瘀”理论运用益肾清利活血法分期诊治慢性肾脏病的经验The Study of Professor Sun Wei’s “Kidney Deficiency and Damp Stasis” Theory on Etiology and Pathogenesis and “Yishen Qingli Huoxue Therapy” in Chronic Kidney Disease[J]. 临床医学进展, 2018, 08(09): 785-789. https://doi.org/10.12677/ACM.2018.89131
参考文献References孙伟, 曾安平, 严志林, 等. 湿热病邪与慢性肾病关系探讨——附152例临床资料分析[J]. 中医研究, 2000, 13(1): 36-37.高坤, 孙伟, 周栋, 等. 慢性肾脏病中医证型分布及演变规律研究[J]. 江苏中医药, 2008, 40(6): 33-35.孙伟. 益肾清利活血治疗慢性肾脏病精粹[J]. 江苏中医药, 2011, 43(2): 1-4.刘芳, 刘金星. 慢性肝病患者血清TGF-β1与肝纤维化指标和肝组织病理的关系[J]. 世界华人消化杂志, 1999, 7(6): 519-521.Liu, Y. (2004) Epithelial to Mesenchymal Transition in Renal Fibrogenesis: Pathologic Significance, Molecular Mechanism and Therapeutic Intervention. Journal of American Society of Nephrology, 15, 1-12.
<br>https://doi.org/10.1097/01.ASN.0000106015.29070.E7Efstratiadis, G., Divani, M., Katsioulis, E., et al. (2009) Renal Fibrosis. Hippokratia, 13, 224-228.Sato, M., Muragaki, Y., Saika, S., et al. (2003) Targeted Disruption of TGF-β1/Smad3 Signaling Protects against Renal Tubulo Interstitial Fibrosis Induced by Unilateral Ureteral Obstruction. Journal of Clinical Investigation, 112, 1486-1494. <br>https://doi.org/10.1172/JCI200319270Zhou, L., Fu, P., Huang, X.R., et al. (2012) Mechanism of Chronic Aristolochic Acid Nephropathy: Role of Smad3. American Journal of Physiology-Renal Physiology, 298, 1006-1017. <br>https://doi.org/10.1152/ajprenal.00675.2009Hao, S., He, W., Li, Y., et al. (2011) Targeted Inhibition of β-Catenin/CBP Signaling Ameliorates Renal Interstitial Fibrosis. Journal of American Society of Nephrology, 22, 1642-1653. <br>https://doi.org/10.1681/ASN.2010101079Liu, M.N., Liu, L.M., Bai, M., et al. (2018) Hypoxia-Induced Activation of Twist/miR-214/E-Cadherin Axis Promotes Renal Tubular Epithelial Cell Mesenchymal Transition and Renal Fibrosis. Biochemical and Biophysical Research Communications, 495, 2324-2330. <br>https://doi.org/10.1016/j.bbrc.2017.12.130Cheng, Z.Y., Liu, L., Wang, Z., et al. (2018) Hypoxia Activates Src and Promotes Endocytosis Which Decreases MMP-2 Activity and Aggravates Renal Interstitial Fibrosis. International Journal of Molecular Sciences, 19, 581.
<br>https://doi.org/10.3390/ijms19020581Yan, D. and Choi, M.E. (2014) Regulation of Autophagy by TGF-β: Emerging Role in Kidney Fibrosis. Seminars in Nephrology, 34, 62-71. <br>https://doi.org/10.1016/j.semnephrol.2013.11.009窦晨辉, 万毅刚, 孙伟, 等. 中药延缓慢性肾脏病进展的机制[J]. 中国中药杂志, 2009, 34(8): 939-943.何伟明, 孙伟. 早中期慢性肾衰中医药证治思路探讨[J]. 江苏中医药, 2009, 41(10): 4-6.卢祖礼, 王小琴. 浅析肾纤维化的中医病机[J]. 湖北中医杂志, 2004(11): 18-19.万冰莹, 孙伟. 孙伟运用补肾清利活血法治疗慢性肾脏病经验[J]. 山东中医杂志, 2016(12): 1053-1055.刘志会, 孙伟. 孙伟教授治疗慢性肾衰竭经验[J]. 河南中医, 2010(2): 137-138.朱莺, 孙伟. 孙伟治疗慢性肾炎对药应用经验撷菁[J]. 辽宁中医杂志, 2007, 34(5): 564-565.孙伟, 高坤, 何伟明, 等. 黄芪治“肾”的研究[J]. 中华中医药学刊, 2008, 26(2): 241-242.王鑫, 孙伟. 益肾清利活血方联合雷公藤多苷片治疗慢性肾脏病4期患者临床观察[J]. 辽宁中医药大学学报, 2013, 15(8): 198-200.吴汉利, 孙伟. 益肾清利活血法对肾虚湿瘀蛋白尿患者尿足细胞排泄的影响[J]. 中国医药导报, 2017, 14(7): 81-85.严志林, 孙伟. 湿热与原发性肾小球疾病关系的临床研究[J]. 河南医药信息, 4(7): 40-41.孙伟. 湿热之邪在慢性肾炎进展中的作用[J]. 江苏中医药, 2006, 27(6): 6-7.孙伟. 清利药在慢性肾病中的应用[J]. 江苏中医, 1991, 10: 20.蒋春波, 孙伟. 孙伟教授治疗肾病对药应用经验拾萃[J]. 现代中西医结合杂志, 2010, 19(9): 1106-1107.赵青, 万毅刚, 孙伟, 等. 黄葵胶囊对阿霉素肾病肾组织炎症信号通路p38MAPK的干预作用[J]. 中国中药杂志, 2012, 37(19): 2926-2935.孙伟. 泄浊之品在慢性肾功能不全治疗中的作用[J]. 江苏中医药, 2007, 39(7): 7-8.沙鑫. 孙伟教授运用泄浊解毒法治疗慢性肾脏病阐微[J]. 山东中医药大学学报, 2017, 41(2): 131-133.涂玥, 孙伟, 顾刘宝, 等. 大黄酸调控mTOR信号通路活性抑制肾小管上皮细胞自噬蛋白表达的分子机制[J]. 中国中药杂志, 2014, 39(21): 4090-4095.刘红, 孙伟, 顾刘宝. 大黄素诱导自噬改善顺便导致肾小管细胞损伤机制探索.世界科学技术—中医药现代化探索[J]. 2017, 19(3): 529-536.高坤. 孙伟教授以益肾清利活血法治疗慢性肾小球疾病的经验[J]. 江苏中医药, 2004, 25(11): 19-21.孙伟, 高坤, 周栋. 益肾清利活血综合治疗局灶节段性肾小球硬化22例分析[J]. 中国中西医结合肾病杂志, 2005, 6(1): 33-34.张露, 周栋, 魏明刚, 等. 益肾清利、和络泄浊法配合治疗早中期CKD40例临床研究[J]. 江苏中医药, 2010, 42(10): 23-24.朱玮玮, 孙伟. “益肾清利、和络泄浊”法对延缓中老年CKD3期患者病情进展的临床观察[J]. 中国继续医学教育, 2017, 9(25): 109-111.郭建红, 孙伟. 孙伟应用益肾清利活血法治疗慢性肾脏病4期经验[J]. 山东中医药大学学报, 2016(4): 354-356.王旭方, 朱玮玮, 佘阿敏, 等. 益肾活性解毒方对慢性肾脏病3期患者肾功能的影响[J]. 中医药导报, 2016, 22(16): 63-64.孙伟, 高坤, 周栋, 等. 益肾清利活血综合疗法治疗局灶节段性肾小球硬化及IgA肾病患者64例临床观察[J]. 中医杂志, 2005, 16(10): 753-755.